Key result
Paclitaxel-eluting balloon angioplasty linked to ~13% cumulative MACE rate at nearly two years.
Why the study?
The safety and efficacy of drug-coated balloons for coronary revascularization across a wide spectrum of clinical and angiographic situations at long-term follow-up were not well established.
Cohort (n=110)
Paclitaxel-eluting balloons demonstrate a low rate of complications and adequate long-term efficacy across a wide spectrum of clinical and angiographic situations, particularly for in-stent restenosis.
Supports paclitaxel-eluting balloon use for in-stent restenosis; leaves open need for randomized confirmation versus alternatives.
AIMS: This study aimed to evaluate safety and efficacy of drug-coated balloon (DCB) at long-term follow-up; a large series of real-life patients underwent revascularization with DCB for a wide spectrum of clinical and angiographic situations. METHODS AND RESULTS: One hundred ten patients underwent percutaneous revascularization using paclitaxel eluting balloon (Sequent Please, Braun, Germany). End-points were major adverse cardiac events (MACE; all-cause death, myocardial infarction [MI], target vessel revascularisation [TVR], and vessel thrombosis). DCB were used for stable angina (58%), unstable angina/nonST elevation MI (31%) and ST elevation MI (11%). DCB were used for in-stent restenosis (61%), small vessel disease (25%), with bare metal stent (BMS) to avoid long dual antiplatelet therapy (10%) or for impossibility to place a stent (4%). Cumulative MACE at follow-up (median 23 months, IQR 13-32) was 12.7%, with 8.2% all-cause death (1 fatal MI), 4.5% TVR, 3.6% TLR, and no vessel thrombosis. Three of four TLRs occurred in patients who received DEB for DES restenosis. CONCLUSIONS: DCB are a very effective tool for a variety of clinical and angiographic situations. DCB use seems to be affected by a low rate of complications and adequate results at long-term follow-up.
No takes yet. Share an insight, caveat, or question.
Pastormerlo et al. (2014) conducted a cohort in Coronary artery disease (n=110). Paclitaxel eluting balloon was evaluated on Major adverse cardiac events (MACE; all-cause death, myocardial infarction, target vessel revascularisation, and vessel thrombosis). Percutaneous coronary revascularization using a paclitaxel-eluting balloon was associated with a 12.7% cumulative rate of major adverse cardiac events at a median follow-up of 23 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: